ProCE Banner Activity

How I Test for FGFR Alterations in Bladder Cancer and Manage Targeted Therapies

Clinical Thought
An expert’s thoughts on what healthcare professionals need to know about FGFR alterations and targeted therapies for bladder cancer.

Released: April 30, 2021

Expiration: April 29, 2022

No longer available for credit.

Share

Faculty

Andrea Necchi

Andrea Necchi, MD

Associate Professor
Department of Medical Oncology
Vita-Salute San Raffaele University
Director, Genitourinary Medical Oncology
IRCSS San Raffaele Hospital and Scientific Institute
Milan, Italy

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen Pharmaceutica NV

Faculty Disclosure

Primary Author

Andrea Necchi, MD

Associate Professor
Department of Medical Oncology
Vita-Salute San Raffaele University
Director, Genitourinary Medical Oncology
IRCSS San Raffaele Hospital and Scientific Institute
Milan, Italy

Andrea Necchi, MD, has disclosed that he has received funds for research support from AstraZeneca, Incyte, and Jansen and consulting fees from Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Incyte, Jansen, Merck, and Roche/Genentech.